1. Drug-induced interstitial lung disease in tyrosine kinase inhibitor therapy for non-small cell lung cancer: a review on current insight

   • Ji Hye Min
   • Ho Yun Lee
   • Kyung Soo Lee

   Mini Review 13 September 2011 Pages: 1099 - 1109

   

2. Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study

   • Keith T. Flaherty
   • Chetan Lathia
   • Peter J. O’Dwyer

   Original Article 25 February 2011 Pages: 1111 - 1118

   

3. Phase I trial of metronomic oral vinorelbine in patients with advanced cancer

   • Lakshmi Rajdev
   • Abdissa Negassa
   • Joseph A. Sparano

   Original Article 04 March 2011 Pages: 1119 - 1124

   

4. The iron chelator Dp44mT inhibits the proliferation of cancer cells but fails to protect from doxorubicin-induced cardiotoxicity in spontaneously hypertensive rats

   • V. Ashutosh Rao
   • Jun Zhang
   • Emily B. Shacter

   Original Article 04 March 2011 Pages: 1125 - 1134

   

5. Aflibercept-mediated early angiogenic changes in aggressive B-cell lymphoma

   • Martha Romero
   • Josette Brière
   • Anne Janin

   Original Article 05 March 2011 Pages: 1135 - 1143

   

6. Preclinical evaluation of the antitumor activity of bortezomib in combination with vitamin C or with epigallocatechin gallate, a component of green tea

   • Bret Bannerman
   • Ling Xu
   • Allison Berger

   Original Article Open access 13 March 2011 Pages: 1145 - 1154

   

7. Thiopurine methyltransferase polymorphisms and mercaptopurine tolerance in Turkish children with acute lymphoblastic leukemia

   • Meryem Albayrak
   • Uljan Konyssova
   • Ulker Kocak

   Original Article 13 March 2011 Pages: 1155 - 1159

   

8. Drug combinations with quercetin: doxorubicin plus quercetin in human breast cancer cells

   • Davide Staedler
   • Elita Idrizi
   • Lucienne Juillerat-Jeanneret

   Original Article 13 March 2011 Pages: 1161 - 1172

   

9. First-line treatment of pancreatic cancer patients with the combination of 5-fluorouracil/folinic acid plus gemcitabine: a multicenter phase II trial by the CONKO-study group

   • Uwe Pelzer
   • Dirk Arnold
   • Helmut Oettle

   Original Article 15 March 2011 Pages: 1173 - 1178

   

10. Accumulation and distribution of doxorubicin in tumour spheroids: the influence of acidity and expression of P-glycoprotein

    • Howard R. Mellor
    • Richard Callaghan

    Original Article 15 March 2011 Pages: 1179 - 1190

    

11. Population pharmacokinetics and pharmacogenetics of vincristine in paediatric patients treated for solid tumour diseases

    • Romain Guilhaumou
    • Nicolas Simon
    • Caroline Solas

    Original Article 14 December 2010 Pages: 1191 - 1198

    

12. A multicenter, randomized, open-label study to assess the steady-state pharmacokinetics of bevacizumab given with either XELOX or FOLFOX-4 in patients with metastatic colorectal cancer

    • Jianguo Zhi
    • Eric Chen
    • David Goldstein

    Original Article 16 March 2011 Pages: 1199 - 1206

    

13. Bevacizumab-related arterial hypertension as a predictive marker in metastatic colorectal cancer patients

    • Alfonso De Stefano
    • Chiara Carlomagno
    • Sabino De Placido

    Original Article 16 March 2011 Pages: 1207 - 1213

    

14. Phase II study of FOLFOX4 with “wait and go” strategy as first-line treatment for metastatic colorectal cancer

    • Mitsugu Kochi
    • Wataru Ichikawa
    • Toshifusa Nakajima

    Original Article 17 March 2011 Pages: 1215 - 1222

    

15. Trabectedin has a low cardiac risk profile: a comprehensive cardiac safety analysis

    • Claudia Lebedinsky
    • Javier Gómez
    • Carmen Kahatt

    Original Article 18 March 2011 Pages: 1223 - 1231

    

16. A phase I study of tasisulam sodium (LY573636 sodium), a novel anticancer compound in patients with refractory solid tumors

    • George R. Simon
    • Robert L. Ilaria Jr.
    • David R. Spriggs

    Original Article Open access 23 March 2011 Pages: 1233 - 1241

    

17. A novel method for quantification of gemcitabine and its metabolites 2′,2′-difluorodeoxyuridine and gemcitabine triphosphate in tumour tissue by LC–MS/MS: comparison with ¹⁹F NMR spectroscopy

    • Tashinga E. Bapiro
    • Frances M. Richards
    • Duncan I. Jodrell

    Original Article Open access 23 March 2011 Pages: 1243 - 1253

    

18. Pharmacologic and phenotypic study of docetaxel in patients with ovarian or primary peritoneal cancer

    • William C. Zamboni
    • Austin J. Combest
    • Joseph L. Kelley

    Original Article 25 March 2011 Pages: 1255 - 1262

    

19. Single nucleotide polymorphisms of CYP19A1 predict clinical outcomes and adverse events associated with letrozole in patients with metastatic breast cancer

    • In Hae Park
    • Yeon-Su Lee
    • Byung-Ho Nam

    Original Article 27 March 2011 Pages: 1263 - 1271

    

20. Role of 12-lipoxygenase in regulation of ovarian cancer cell proliferation and survival

    • Austin M. Guo
    • Xiuli Liu
    • Adnan R. Munkarah

    Original Article 29 March 2011 Pages: 1273 - 1283

    

21. Sorafenib for hepatocellular carcinoma according to Child-Pugh class of liver function

    • Jeong Eun Kim
    • Baek-Yeol Ryoo
    • Yoon-Koo Kang

    Original Article 29 March 2011 Pages: 1285 - 1290

    

22. Efficacy and pharmacokinetic/pharmacodynamic evaluation of the Aurora kinase A inhibitor MLN8237 against preclinical models of pediatric cancer

    • Hernan Carol
    • Ingrid Boehm
    • Richard B. Lock

    Original Article Open access 30 March 2011 Pages: 1291 - 1304

    

23. Pre-treatment lymphopenia as a prognostic biomarker in colorectal cancer patients receiving chemotherapy

    • N. Cézé
    • G. Thibault
    • T. Lecomte

    Original Article 30 March 2011 Pages: 1305 - 1313

    

24. Furanodienone induces cell cycle arrest and apoptosis by suppressing EGFR/HER2 signaling in HER2-overexpressing human breast cancer cells

    • Ying-Wei Li
    • Guo-Yuan Zhu
    • Wang-Fun Fong

    Original Article 03 April 2011 Pages: 1315 - 1323

    

25. Amrubicin for the treatment of neuroendocrine carcinoma of the gastrointestinal tract: a retrospective analysis of five cases

    • Masako Asayama
    • Nozomu Fuse
    • Atsushi Ohtsu

    Original Article 03 April 2011 Pages: 1325 - 1330

    

26. A phase 2 study of weekly albumin-bound paclitaxel (Abraxane^®) given as a two-hour infusion

    • Paul K. Paik
    • Leonard P. James
    • Naiyer A. Rizvi

    Original Article 03 April 2011 Pages: 1331 - 1337

    

27. Methotrexate toxicity and efficacy during the consolidation phase in paediatric acute lymphoblastic leukaemia and MTHFR polymorphisms as pharmacogenetic determinants

    • Velia D’Angelo
    • Maria Ramaglia
    • Fiorina Casale

    Original Article 18 May 2011 Pages: 1339 - 1346

    

28. A phase I-II study of elacytarabine (CP-4055) in the treatment of patients with ovarian cancer resistant or refractory to platinum therapy

    • S. Pignata
    • F. Amant
    • I. Vergote

    Clinical Trial Report 10 September 2011 Pages: 1347 - 1353

    

29. Severe fluoropyrimidine-related toxicity: clinical implications of DPYD analysis and UH2/U ratio evaluation

    • E. Giorgio
    • C. Caroti
    • E. Di Maria

    Short Communication 11 August 2011 Pages: 1355 - 1361

    

30. Pharmacokinetics of trabectedin on hemodialysis: an application for the management of cancer patients with end-stage renal disease

    • Juliette Thariat
    • Marie-Christine Etienne-Grimaldi
    • Antoine Thyss

    Short Communication 18 August 2011 Pages: 1363 - 1367

    

31. MTHFR 677TT genotype and toxicity of methotrexate: controversial results

    • Elixabet Lopez–Lopez
    • Javier Ballesteros
    • Africa Garcia-Orad

    Letter to the Editor 06 August 2011 Pages: 1369 - 1370

32. Reply

    • Velia D’Angelo

    Reply 13 August 2011 Pages: 1371 - 1371